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Abstract
The tumour suppressor p53 is now known to be an ancient transcription factor that had already evolved 
interaction sites with its partner protein MDM2 at the dawn of multi-cellular eukaryotic animal life. The billion-
year life history of the p53-MDM2 axis has permitted significant time for the proteins to integrate into a distinct 
range of cellular pathways including binding to hundreds of genomic promoters and regulatory protein-protein 
interactions with hundreds of distinct functions. This long age of p53 allows us to understand how the protein 
can regulate a range of functions such as energy generation of the cell, cell motility, genome integrity, virus 
infection, immune cell response, ageing, and oxidative stress. Due to this deep integration of p53 into the core 
of eukaryotic life, it is not surprising that the p53 pathway requires inactivation in order for human cancer 
cells to evade the normal growth controlling processes that have been shaped through evolution by natural 
selection. This review will focus on the emerging concepts in the protein science field that shed light on p53 
protein evolution and function including the nature of thermodynamically unstable regulatory proteins and 
the growing realisation that the majority of protein-protein interactions in complex eukaryotic cells are driven 
by intrinsically unstructured and weakly interacting peptide motifs. These concepts help to explain how the 
vast number of dynamic and specific protein-protein interactions in the p53 pathway evolved, suggest how 
amino acid modifications like phosphorylation or acetylation in turn evolved to regulate dynamically the p53 
interactome, and finally reveal therapeutic strategies for targeting the p53 interactome in human cancers.
Intrinsic disorder: the rise of a new 
dogma in protein science that impacts 
upon our understanding of p53
As biologists or biochemists, we have all learned the 
structure-function paradigm that proteins display different 
levels of organisation: a “primary” linear sequence on 
which depends local spatial “secondary” arrangements 
stabilised by a three dimensional compact structure, 
usually referred as globular protein or called native fold, 
i.e. the biologically active form of the protein. Upon 
this structure-function concept several protein-protein 
interaction (PPI) models have been developed such as 
the recent Nobel Prize awarded on solving the structure 
of a ribosome. It is perhaps not a co-incidence that a 
major advance on the road to acquire the structure of this 
prokaryotic multi-protein complex was the decision to 
switch to purifying ribosomal proteins from thermophilic 
bacteria which are more suitable to form stable structures 
using current experimental methodologies. More 
“unstable” ribosomal complexes from, for example, higher 
eukaryotes are not suitable for such crystallographic 
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analysis. What makes these more temperate multi-protein 
complexes “unstable”? 
Despite the fact that the structure-function paradigm 
can explain the mechanism of many protein–protein 
interactions, this paradigm has been “modified” and 
challenged by an increasing awareness of non-folded 
protein regions exhibiting functionality. For example, 
comparing the resolution of protein crystal structures and 
protein sequence banks, only 7% of proteins are devoid 
of any “disorder” pattern and around only 25% exhibit 
>95% of their lengths in their 3D structure. This suggest 
that the vast majority of proteins in the PDB are shorter 
than their corresponding sequence length [1]. From many 
such similar clues, there has emerged a new concept 
in the protein science field that established that there 
are relatively large regions of functional, intrinsically 
unstructured regions, or disordered proteins forming the 
IUP or IDP kingdom.
These natively unfolded components can encompass 
degrees of disorder from the totally disordered protein, 
even large ones, to some locally intrinsically disordered 
region (IDR) that can also be as small as only a few amino 
acid residues. The extent of disorder can vary widely from 
transient local unfolding, to partially strictly unstructured 
regions, to totally unfolded domains, that can be modified 
by sequence variation in amino acid composition and 
nearby environment [2, 3]. In human diseases, examples 
of proteins with extended and large regions of intrinsic 
disorder include the ARF tumour suppressor, the MDM2 
oncoprotein, and the Parkinson disease/cancer associated 
proteins in the synuclein superfamily. 
IUPs throw new light on the flexibility of PPIs  and 
Connectivity of pathways
Since the recognition of their existence, hundreds of 
articles have described cases of intrinsically unstructured 
proteins (IUPs), which led to an analysis of the importance 
of this phenomenon on a genome scale. A study on protein 
disorder from different kingdoms have shown that the 
extent of disorder can be as low as 3% in prokaryotes, 
over 15% in yeast, and over 50% in mammals [4]. This 
forms large information rich landscape composed of 
“unstructured” polypeptide sequence in the proteome 
of higher eukaryotes and forms the basis for expanding 
substantially the numbers of “connections” between 
proteins. Indeed, it has been suggested that one reason 
why higher mammalian life developed, although with 
a similar number of genes to invertebrates, is the large 
increase in novel protein-protein connections driven 
by intrinsically disordered regions, that allow new low 
affinity, reversible but highly specific, signal transduction 
systems to emerge. 
There are wide correlations between the increasing 
amount of disorder in the proteome and the complexity of 
the organism considered. Disordered proteins were shown 
to hold key positions and play roles in more prominent 
pathways in higher organisms such as cell signalling, 
regulation, molecular recognition and control pathways 
rather than metabolic processes where classic structural 
domains reign dominant. These signalling pathways 
require high specificity and, at the same time, low affinity 
so that, that IUPs can adopt stable folds when interacting 
with different partners. These properties allow IUPs to 
nucleate protein hubs that form high interaction networks 
through an unusually large number of dynamic, unstable, 
but functional protein-protein interactions [5, 6]. Indeed, 
IDPs not only enable a single protein to bind a large 
number of partners (at different times) but also allow the 
binding of multiple proteins to a common partner. Thus, 
the lack of “intrinsic” structure becomes a functional 
advantage and gives novel evolutionary adaptive 
benefits in fine-tuning or allowing a change in molecular 
interaction networks. IUPs/IDRs involved in protein-
protein interactions display several special features listed 
below in comparison with “ordered” proteins/regions. 
These properties emerge in essential requirements for 
weak, rapid, transient, promiscuous, reversible, specific 
and also highly regulated protein-protein interactions 
that so much exploited in signalling and regulation [7]. 
Understanding protein-protein interactions mediated by 
IUPs would help to map interactome to decipher complex 
mechanisms that are involved in pathologies like cancer 
or neurodegeneration.
Specific properties of IUPs: state-of-the-art interface, 
folding coupled to binding, preformed structure
IUPs or IDRs are classified by a negative, a non well-
defined 3D structure. But this unstructured state is not 
synonymous with a denatured state, as point mutations 
can affect the activity thus demonstrating that the IUP 
or IDR contains somehow the propensity to acquire 
structure [8]. Disordered proteins showed different 
chemical and physical features, compared to globular 
counterparts, including their composition and interface 
sequences. The overall amino acid composition of an 
IUP or IDR is enriched in amino acids of high flexibility 
indexes with disorder promoting amino acid such as Ala, 
Arg, Gly, Gln, Ser, Pro, Glu or Lys. These confer a high 
net charge and a low net hydrophobicity to the IUPs/IDRs 
that ensure an extended state and an inability to fold, 
naturally. In term of interface area, their hydrophobic 
residues are more exposed than buried in contrast with 
the hydrophobic core of a globular protein [9]. As IUPs 
exploit hydrophobic-hydrophobic interactions and as 
they exploit a larger relative interface area, they engage 
a larger number of contacts that drive a better fit with a 
partner. Moreover IUPs in 70% of the cases use a single 
continuous segment for partner binding as opposed to 
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ordered protein interfaces that are more segmented [10].
All of these differences within disordered proteins 
manifest themselves in interaction energies. Alone, a 
disordered protein can’t necessarily fold into a stable 
manner because of lower number of inter-residue 
interactions compared to an ordered protein. In fact 
IUPs gain stabilisation energy from their intermolecular 
contacts in the presence of a partner, this binding can 
induce a large-scale folding of the IUP. Various models 
emerge from this folding upon binding; such as fly-
casting which states that the flexibility of disordered 
structures enables a weak and not so specific binding 
to evolve into a folded and thus specific binding to a 
partner [10, 11]. The principal feature of IUPs is their 
pliability toward a wide range of partners revealed in 
multiplicity of accessible structural states separated by 
low energy barriers. IUPs could adopt different folds that 
can be a well-defined 3-D structure, when interacting 
with different partners. Therefore IDRs would possess 
inherent conformational preferences leaded by a residual 
preformed structure [9].
 
Molecular recognition features and short linear 
motifs
In order to recognise their partners, IUPs often use 
sequential molecular recognition element/features 
(MoREs/MoRFs) imparting specificity to PPIs. MorFs 
are short region of order-promoting residues (10-70 
amino acids) flanked by IDRs and are characterised by 
some aspects previously discussed as they fold upon 
binding and contain some pre-existing structure [12, 
13]. There are three different types of MoREs: those that 
form an a-helix upon binding with a partner (a-MoRE); 
those that form b-strands (β-MoRE); and those that form 
irregular structures (I-MoRE) [12]. It has been shown 
that short linear motifs or SLiMs (3-10 amino acids) in 
proteins often fall (around 85%) into locally disordered 
regions. These short functional sequence patterns capture 
key residues involved in function or binding. For example 
they can correspond to a region including a critical site 
for modifications as phosphorylation or localisation 
signals like KDEL. Identifying linear motifs could help 
to find binding partners and explain how one protein is 
able to bind so many different partners, but also could 
be instructive about their biological functions and how 
interaction networks are constructed [14]. So far only 
hundreds of linear peptides have been identified. There 
are likely still numerous linear motifs yet to be discovered 
as they are difficult to discover [15]. Different interaction 
studies have attempted to capture them computationally at 
a genome-scale, rather than one by one slow experimental 
discovery process [15]. In term of evolutionary plasticity, 
they can be switched on and off quite easily by point 
mutation. Consequently they are often poorly conserved 
(as in the striking divergence between the murine and 
human ARF tumour suppressor), but different species 
would use the same kind of motifs that have eventually 
arisen convergently [16].
The disordered binding region (MoRFs) and the 
linear motif concepts describe molecular interactions on 
different bases: the first one focuses on the structure and 
the second approaches the problem through the sequence. 
However, the interactions described by the two concepts 
describe two aspects of the same phenomenon as in both 
cases the interaction is confined to a relatively short, 
continuous region in one of the partners. The study of 
MoRF and SLiM connection is still ongoing [17].
Conservation of the interface of IUPs
As the increase in disorder has been shown to correlate 
positively with regulatory functions that have undergone 
expansion between bacteria and higher multicellular 
eukaryotes, a closer look at the evolution of genes coding 
for intrinsically disordered proteins could explain the 
changes in an IUP interactome. Disordered regions 
don’t display any significant evolutionary conservation 
compared to structured regions in proteins, and this 
makes them relatively difficult to identify. Regions 
which become ordered upon complex formation are 
more conserved, especially key residues in an molecular 
interface [10]. Within a same family of a gene or a 
single gene, disordered proteins/regions are able to 
undergo rapid evolution preserving functionality without 
degenerating into a pseudogene. Faster evolution within 
these disordered regions compared to globular region, 
due sometimes to gene duplication, repeat expansion, 
and mutations explains that IDPs/IDRs are commonly 
more difficult to find by sequence similarity. We can 
imagine subsequently that cells possess a stunning 
evolutionary tool to adjust a protein-protein network or 
network cross-talk to respond to new selection pressures 
of the environment or epigenetic signalling pathways that 
imprint a change in a cell steady-state [18]. Nonetheless, 
studying the evolution relationship between an IDP and 
its partners might also be harder to follow linearly as 
evolution is not necessary unilateral; co-evolutionary 
adaptive changes of both partner and IDPs can occur [19].
P53 hub, a partially disordered protein 
The P53 signalling protein
The tumour suppressor p53 plays a central role in cancer 
suppression by preventing proliferation of damaged cells 
with potentially cancer-prone mutations through its ability 
to act as a DNA-binding protein and transcription factor, 
whereby it can induce the transactivation of proteins that 
play a role in cell cycle arrest, apoptosis, senescence, 
DNA repair or alter metabolism [20-24]. The p53 gene is 
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one of the most widely mutated genes in human cancer, 
it can be observed in over 50% of all human tumours 
and these tumours respond poorly to therapy [25]. This 
central player in the cancer control artillery is present in 
a low activity state and at low levels under unperturbed 
conditions but becomes rapidly activated in response 
to a variety of stimuli such as UV light, DNA damage, 
virus infection, and overexpressed oncogenes [26]. In 
unstressed cells, p53 is under the negative regulation of 
the murine double minute clone 2 (MDM2) protein that 
mediates the ubiquitination and degradation of p53 by 
the proteasome. P53 transcriptionally activates the mdm2 
gene and because MDM2 inhibits p53 activity, this forms 
a negative feedback loop that regulates p53 function [27].
P53 structure and PPIs
P53 is an extensively studied modular protein of 393 amino 
acids which functions rely on various domains (Figure 1): 
an N-terminal transactivation domain (TAD) subdivided 
into TAD1 (residues 1-40) and TAD2 (40-61); an adjacent 
potential conformational element consisting of a proline-
rich domain (PRD; 64-92); a large DNA-binding domain 
(DBD; residues 93-293); a tetramerisation domain (4D; 
325-356) connected to the DBD via a flexible linker; and 
a basic C-terminal regulatory domain (CTD; 367-393) 
[28]. These domains regulate its function as a stress-
activated sequence-specific DNA-binding protein and 
transcription factor. The primary amino-acid sequence 
of p53, especially the TAD region, contains many post-
translational modifications (Figure 1) that have a crucial 
role in regulating p53 interactions thus its stabilisation 
and activation [29, 30]. Therefore p53 integrates signals 
of multiple signalling pathways by post-translational 
modifications [31, 32]. According to disorder prediction 
software (Figure 1), around 50 to 60% of its residues are 
considered within an intrinsically disordered structure. 
Two regions, amino acids 25-50 at the N-terminus, 
325-350 at the C-terminus, have a higher tendency of 
being structured and are flanked by disordered region; 
another segment around amino acids 150-190 could be a 
disordered region connecting two structured domains at 
both sides within the DBD.
p53 has been extensively studied leading to an 
important number of discovered PPIs that could either 
be created between a disordered p53 segment and an 
ordered partner, either between an ordered p53 segment 
and a disordered partner, or also between two disordered 
p53 segments as it is likely in the p53 tetramer formation. 
So far 485 partners according to BioGRID database, 
266 direct protein interactors according to the Human 
Protein Reference Database, 303 according Interologous 
Interaction Database (SwissProt ID: P04637, 315 from 
POINeT database, have been brought forward by different 
experimental methods (Figure 2). Both TAD and CTD are 
Figure 1. Sites of post-translational modifications and structure of p53. Post-translational modification sites are represented 
by vertical ticks [31, 32]. Experimentally structured region corresponds to crystallised DNA-binding domain. The dashed line at 
0.5 of Y-axis is threshold line for disordered/structured residues. Residues with a score above this latter are predicted disordered 
and with a score below are predicted to be ordered. DisProt VSL2B [33], PONDR VL-XT [34] and IUPred [35] correspond 
to the prediction from the predictor of the same name. All features are represented to scale as indicated by the horizontal axis.
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Figure 2. P53 protein interaction network. A) Experimental human p53 non-redundant interactors build with POINeT whose protein-
protein interaction data sources are from BIND, AfCS, HPRD, BioGRID, MPact, DIP, IntAct, NCBI interactions, MINT, MIPS databases 
(http://poinet.bioinformatics.tw). B) P53, p63 and p73 interaction networks from Interologous Interaction Database visualised with 
NAVIGatTOR 2.1.13 software. This p53 family network displays interplays as it exhibits common interactors between the two and/or three 
of them. I2D (Interologous Interaction Database) is an on-line database of known and predicted mammalian and eukaryotic protein-protein 
interactions (http://ophid.utoronto.ca).
especially multi-functional binding sites for a multiple of 
interacting proteins. For examples among many others, 
p53 TAD region interacts with TFIID, TFIIH, MDM2, 
RPA, CBP/p300 and CSN5/Jab1 and the CTD domain 
interacts with GSK3b, PARP-1, TAF1, TRRAP, hGcn5, 
TAF, 14-3-, S100ββ [36].
Post-translational modifications
In addition to the vast number of protein-protein 
interactions, p53 is also subjected to covalent modifications 
such as phosphorylation that can regulate its specific 
activity [37]. Post-translational modifications (PTMs) 
are essential for signalling as they affect protein turnover, 
stability, localisation but also interaction properties and 
thereby affect deeply the protein function. Recent studies 
have shown that most phosphorylation sites, as well as 
acetylation and methylation sites are not localised within 
ordered regions but are located in unstructured parts of 
proteins. Indeed, p53 has many phosphorylation sites 
in its intrinsically disordered regions [31], with one of 
the most recently identified phosphorylation sites in the 
conformational flexible DNA binding domain whose 
phosphorylation drives wt-p53 into an unfolded mutant-
like state [38, 39]. By extension it is likely that other 
modifications such as ubiquitination, sumoylation, or 
neddylation will be more often found in unstructured 
protein segments and these modifications might similarly 
prime p53 for conformational changes that impact on its 
function or stability. These different PTMs create a pattern, 
just like a “binding code”, as they can modify the local 
charge density and hydrophobicity, and in this manner 
affect the structure and the folding properties of the local 
chain and its surface [11]. Overall, PTMs are providing 
dynamicity in the PPIs mediated by IDRs/IUPs and can 
adapt the function accurately in space and time scales to 
fulfil different and specific biological cell outcomes. 
IDRs of p53 and their bound-structures
PONDR VL-XT disorder prediction software was 
applied to the p53 sequence (Figure 1) and resulted in 
the identification of two regions with a MoRE pattern 
within p53 [3, 13]. The first is located between residues 
17-35 which overlaps with p53 binding region to MDM2 
(residues 13-29) and which undergoes a disorder-to-
a-helix transition [13, 40]. The second MoRE resides 
between positions 374-392, which partly cover residues 
367-388 known to fold upon binding to S100b, another 
binding partner of p53 [41]. In addition, the software 
confirmed an order region with only marginal instability 
(residues 100-290) matching almost the identified DNA 
binding domain; and an a-b-MoRE tetramerisation 
domain (residues 320-360) which undergoes mutually 
induced folding by self association in the tetrameric state 
by dimerisation of the dimers [3, 13]. Similar results could 
be obtained with ANCHOR software [42], which seeks 
to predict disordered binding regions able to undergo a 
disorder-to-order transition via binding to a structured 
partner (Figure 3).
The Nter acidic activation domain (TAD) of p53 
consists of a completely unstructured region when 
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Figure 3. Linear peptide docking/binding sites in p53 are correlated with MoRE-pattern binding regions. The overlapping 
but distinct linear binding motifs for p53 function regulators include the acetyltransferase p300 and deacetylase Sirtuin, the 
E3 ubiquitin ligase MDM2, the protein kinases CHK2, CK1, CDK/Cyclin A, CK2, the activator CBP and the repressor S100β 
[31, 43].
free in solution and fold upon binding to their targets. 
This domain is promiscuously a binding site for the 
co-activator p300, components of the transcription 
machinery and the negative regulators MDM2/MDM4 
[44]. In complex with 109-residue amino-terminal of 
MDM2, a 15-residue binding peptide of p53 TAD adopts 
an a-helical conformation (2.5 turns) showed by X-ray 
crystallographic studies. Binding between MDM2 cleft 
and the hydrophobic face of the p53 a-helix relies on 
three deeply inserted amino acids of p53 – 19, 23 and 26 
– which are involved also in p53 transactivation [40]. In 
nuclear magnetic resonance (NMR) and residual dipolar 
coupling studies, a similar single turn helix at the same 
amino acids 22-24 is transiently formed when p53 is free 
in solution, showing that this unstructured region displays 
a preformed structure [45, 46]. Indeed the full-length p53 
TAD was shown by NMR to be populated with preformed 
structures – an amphiphatic helix formed by residues 18-
26 and two nascent turns by residues 40-44 and 48-53 
[46]. The TAD2 including these two latter turns have been 
shown to fold into amphiphatic a-helices upon binding to 
replication protein A and a subunit of yeast TFIIH [44].
Interestingly, same highly basic IDR of p53 (residues 
374-388), which is subject to extensive regulatory post-
translational modifications (Figure 1), is able to fold in a 
partner-depending manner into three different secondary 
structures in the bound state (Figure 4): a a-helix when 
interacting with S100b [41], a b-sheet with sirtuin [47], 
an irregular structure with CBP [48] and another irregular 
one with cyclin A2 [49]. Analysis indicated that the same 
residues are involved in the four interfaces suggesting 
that this region includes a “code” read differently by 
the different partners which induces different binding 
characteristics [9, 50]. The function of the CTD is 
only partially understood with some controversy in the 
literature about its role in vivo.
Quaternary structure of p53
The structure of full length p53 in a tetrameric state bound 
to DNA and TAD-binding Taz2 domain of p300 (which 
both reduced the flexibility of p53) and free in solution has 
been unveiled by a combination of different techniques 
such as small-angle X-ray scattering and electron 
microscopy [44, 51]. The free full-length p53 displays 
a cross-shaped tetramer with loosely coupled DBD and 
extended TAD and CTD. Free p53 is a heterogeneous 
population with mainly open conformation. Interestingly 
murine p53 showed a different tetrameric structure formed 
through N and Cter when cryo-EM is applied to the 
recombinant protein. This may reflect the flexibility in the 
p53 tetramer or it may be an artefact of the methodology. 
In the presence of DNA, tetrameric p53 enfolds around 
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Figure 4. Different secondary structures adopted by the same C-terminus segment of human p53 when bound to 
different partners. Region between amino acids 374 and 389 (green) have been shown to become a helix when binding to 
S100ββ  (PDB: 1dt7), a sheet when binding to sirtuin (1ma3), and a coil with two distinct backbone shapes when binding to 
CPB (1jsp) and Cyclin A2 (1h26). Same residues of p53 are used to different extents by the four interfaces.
the DNA helix rendering the overall structure more rigid. 
The extension of the Nter is a common feature in both free 
and DNA-bound p53 representation, allowing multiple 
regulatory interactions [44, 52].
Targeting PPIs to turn on p53
Primarily structure-based drug design were developed 
by focusing on well-ordered active sites, however in the 
past decade a new approach of disorder-based rational 
drug design has lead to alternative promising drugs [53]. 
Identification of small molecules or peptide aptamers 
that specifically target interaction interfaces involving 
unstructured regions may embody a novel drug discovery 
strategy [14]. Due to its involvement in cancer, the p53 
pathway is universally a star pupil in developing innovative 
strategies and mechanisms for drug therapy [54, 55]. 
Indeed for p53 targeting, cis-imidazoline analogs, Nutlins 
have been developed to mimic the p53 a-helix within the 
TAD (Figure 5). Thus these small molecules are able to 
bind really specifically to the hydrophobic cleft of MDM2 
and block the interaction between MDM2 and p53 which 
activates this latter [56, 57]. New leads for therapeutic use 
could be obtain by designing small molecules targeting 
PPIs, approach which requires learning more about them 
through intrinsically disorder structures.
P53 throughout the ages: the origin of 
p53’s disorder
A family of genes: sisters but not twins
P53 has been show to belong to a superfamily of 
related transcription factors with the discovery of two 
homologues p63 and p73 whose structure and function are 
analogous but not identical to those of p53. Their genes 
encode for multiple p63, p73 or p53 proteins containing 
different protein domains (isoforms) due to multiple 
splicing, alternative promoter and alternative initiation of 
translation. Studies on the p53 gene structure established 
that it encodes 9 different protein isoforms [58-60]. 
The human p53 orthologues displays a dual structure 
conserved in Drosophila and zebrafish, which underlies 
the importance of the various roles of isoforms [61]. P53, 
p63 and p73 appear to possess overlapping and distinct 
functions: p53 is essential as a tumour suppressor, as a 
pro- or anti-ageing factor, and it can induce cell death and 
growth arrest; p63 is essential for ectoderm development; 
and p73 might regulate both stress response with tumour 
suppression role as well, and development/differentiation 
[62-64]. However p73 and p63 have been both shown to act 
as tumour suppressors and are being associated with new 
pathways linked or not with p53 [65]. As they are able to 
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Figure 5. Structural application to p53 structure-based drug therapies. The crystal structure of nutlin (blue) in complex 
with MDM2 (grey) mimics the three residues from p53 (red) that are involved in p53-MDM2 interaction (left: 1rv1; right: 
1ycr).
target common genes and to form heterocomplexes, there 
is no doubt that this trio participate in a complex interplay 
by interfering and collaborating with one another.
From their disorder profiles (PONDR VL-XT data), 
p63, p73 and p53 overall disordered percentages are 
respectively 50.59%, 55.03% and 49.11%. Analysis of 
these disorder profiles against the schematic representation 
of p63 and p73 [66] revealed a similar disorder/order 
pattern for both proteins (Figure 6). Respectively for p63 
and p73, three or two ordered potential binding regions 
lie within the disordered TAD. Both PRDs and regions 
between 4D and sterile a motif (SAM) domain are 
highly disordered in contrast with the structured DBDs. 
Nevertheless DBDs show a region of 100 amino acids 
similar to p53 DBD that have a tendency to be disordered 
and which could undergoes a transition disorder to order 
upon DNA binding. In comparison with p53, the NLS 
is also disordered but display a sharp ordered motif and 
4D domains are also disordered with two binding motifs. 
Lastly, p63 and p73 possess a unique ordered SAM domain 
and their CTDs are disordered with a large ordered motif 
or two closed motifs within these latter similarly to p53 
CTD.
The p63 and p73 proteins possess only one TAD 
homologous to the TAD1 of p53. Thus, the N-terminus 
is the least conserved domain among the p53 family 
members, but at the same time, both p63 and p73 can 
activate sets of p53 target genes, and moreover key 
residues for some interactions such as p53-MDM2 are 
conserved within the family. The helical propensity of the 
region previously discussed in p53 structure properties 
within its TAD is similar for p53 and the analogous 
region of p73, but is lower for p63, which could explain 
different behaviour towards partners. In addition, PTMs 
as phosphorylation can perturb or enhance helicity of this 
region that will enable dissociation with some partners or 
tighter association with some others [67]. 
The main difference between p53 family members 
resides in the C-terminus (Figure 1 and 6) as p53 contains 
a basic domain natively unfolded and the site of numerous 
PTMs, whereas p63 and p73 possess a sterile ordered 
a motif and an unstructured region C-terminal to the 
SAM domain which is called transcriptional inhibitory 
domain (TID). This C-terminus can be spliced in some 
isoforms and these latter truncated isoforms are more 
transcriptionally active which underlies the regulatory 
function of the C-terminus similarly than the p53-CTD 
[66, 68]. The SAM domain is a globular domain composed 
of a five-helix bundle topology and is important for the 
stability of the oligomerisation domain as it stabilised 
it [69]. This C-terminus ordered domain of p63/p73 
is essential of stabilising the architecture as a tetramer, 
which is lost in mammalian p53 during evolution as this 
latter has acquired through regulating PPIs within its 
disordered CTD [70, 71]. Another divergence between 
members is the presence of an additional helix in the 
oligomerisation domain of p73, which is conserved in 
p63. TD domain that is essential for the formation of 
tetramers is the only active form of p53 for stable DNA-
binding and subsequent gene transactivation. Differences 
in the structural domains within p53 family members 
within the same organism are responsible for the diversity 
of their various functions, so it can be extent easily to p53 
from different organisms, whose structure evolution lead 
to modify its interactome and thus its functions. 
Origins, evolution and role of disorder in p53
Overall, p53 forms an ancient regulatory network with 
MDM2 and is fundamentally linked to adaptative stress 
responses governing in a first instance germ-line regulation, 
then was shaped to control fidelity of reproduction, 
development and longevity, to finally specialise as a 
tumour suppressor to protect cells from aging and cancer, 
in not only gametes but in every somatic cells in higher 
organisms [72-74]. Neither the p53 nor MDM2 family is 
known to be present in bacteria, archaebacteria, yeast, or 
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Figure 6. Schematic representation and disorderness of p63 and p73. The dashed line at 0.5 of Y-axis is threshold line 
for disordered/structured residues. Residues with a score above this latter are predicted disordered and with a score below are 
predicted to be ordered. DisProt VSL2B [33], PONDR VL-XT [34] and IUPred [35] correspond to the prediction from the 
predictor of the same name. All features are represented to scale as indicated by the horizontal axis.
plants, but it is now believed to have emerged in response 
to selective pressures on early multicellular organisms in 
the Animalia kingdom (metazoans). Indeed, p53 (27% 
identity with human p53) and MDM2 have both been 
shown to be present in Placozoans (Trichoplax adherans), 
one of the simplest multicellular organisms as it displays 
three different cell types [75]. This discovery pushed back 
the evolutionary history of p53 and MDM2 as co-factors 
to a billion years. However, equally amazingly, although 
p53 and MDM2 generally persist together throughout 
insect and urochordate life, they have been strikingly 
lost in the famous 20th century model organisms used by 
scientists, Drosophila melanogaster and Caenorhabditis 
elegans. The loss of p53 and MDM2 in these two model 
organisms is a blow to our ‘having a ready-to-use genetic’ 
system to dissect out the fundamentals of the p53-MDM2 
axis, but nevertheless highlights that we could perhaps 
develop other invertebrates as genetic models to study 
p53 and MDM2 in the decades to come. 
Interestingly, other genomes have been used to 
examine the origin of p53 within the Animalia branch. 
Two p53 paralogs (a p53-like sequence and a p63/73-like 
sequence) are present in a choanoflagellate (Monosiga 
brevicollis), a free-living unicellular and colonial 
eukaryotes considered to be the closest living relatives 
of the animals [76, 77]; also a p53-like protein could 
have been discovered in a amoeba genome (Entamoeba 
histolytica) which is an anaerobic parasitic protozoan 
[78]. Lastly, a putative p53 homologue has been shown in 
maize with possible involvement during DNA replication 
and growth control at an embryo germination level [79, 
80]. Consequently, the emergence of p53 family might 
have predated the appearance of metazoans, but seems to 
have appeared within eukaryotic cells, perhaps set apart 
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from prokaryotic cells by the presence of a chromatin-
constrained nucleus, which interestingly is essential for 
p53 subcellular distribution that is central for its regulation 
and functions.
Lastly, it is interesting to underlie that from a 
complexity point of view Monosiga should be closer to 
the common ancestor form of the p53-like protein, but 
the p53-like protein from Trichoplax adherans is closer 
to any other p53-like protein from human through to 
choanoflagellate (Figure 7). The extent of disorder seen 
in the p53 amino acid sequence might have been quite 
prominent a billion years ago (Figure 7), which implies 
the protein had already found a way to use this strategy as 
a means for regulating flexible, low affinity, but specific 
protein-interaction hubs as it started on the road to imbed 
itself into many dominant pathways in eukaryotes. 
Organism NCBI accession
number
Protein length 
(residues)
Overall % 
disorder
Overall % 
identity
DBDs % identity compared 
to one organism
Homo sapiens NP_000537.3 393 49.11 100 100 40 21
Rattus norvegicus NP_112251.2 391 52.43 76 90 43 21
Danio renio NP_571402.1 373 52.55 47 69 40 24
Caenorhabditis elegans NP_001021478.1 644 37.89 4 8 19 16
Drosophila melanogaster NP_996267.1 495 34.55 11 18 24 11
Ciona intestinalis NP_001122370.1 489 52.35 29 38 38 25
NP_001071796 419 36.52 27 39 36 21
Nematostella vectensis EF424411.1 378 50.53 23 36 38 20
EF424412.1 369 31.17 21 32 32 17
Trichoplax adhaerens XP_002113784.1 576 37.50 27 40 100 23
Monosiga brevicollis XP_001747656.1 571 49.21 18 21 23 100
A
Homo_sapiens                    ----LSSSVPSQKTY-QGSYGFRLGF----------------LHSGTAKS 
Rattus_norvegicus               ----LSSSVPSQKTY-QGNYGFHLGF----------------LQSGTAKS 
Danio_renio                     ----PTSTVPETSDY-PGDHGFRLRF----------------PQSGTAKS 
Ciona_intestinalis_489          ----SKPTIPPSTDY-PGEWDFQINFGE--------------ATESAPKS 
Ciona_intestinalis_419          ----TEVSLLPNNEY-PGIYNFEINFGE--------------KTESAPKS 
Nematostella_vectensis_378      ----HLPTIPSTAEY-PGELGFCVSFGP--------------PTESASKS 
Trichoplax_adhaerens            ----RDPSLPSNAEY-IGNFGFDIAID---------------QNDNPTKA 
Nematostella_vectensis_369      ----HHVIAPSSDEV-PGEYSFKLTLET--------------QPKKVAN- 
Drosophila_melanogaster         DIQIQANTLPKLENHNIGGYCFSMVLD-------------------EPPK 
Monosiga_brevicollis            -----DLTLLQNGSAPIPISSNSLHVPC--------------RWPHFDVL 
Caenorhabditis_elegans          QMDFTETNVPFDGNDESSNLAVRVQSDMNLNEDCEKWMEIDVLKQKVAKS 
                                                       :                          
Homo_sapiens                    VTCTYSPA---LNKMFCQLAKTCPVQLWVD-------------------- 
Rattus_norvegicus               VMCTYSIS---LNKLFCQLAKTCPVQLWVT-------------------- 
Danio_renio                     VTCTYSPD---LNKLFCQLAKTCPVQMVVD-------------------- 
Ciona_intestinalis_489          AQYTYSPI---INKLFVKMNVTCPIKFKCA-------------------- 
Ciona_intestinalis_419          APFTYSYS---LQKLFVKMNENCPIKFRCS-------------------- 
Nematostella_vectensis_378      ATWTYSEK---CKKLYVNLASFCPIKFKTT-------------------- 
Trichoplax_adhaerens            TNNTYSTM---LKKLFIKMECLFPIHITIERMDYTFKIAYGSLATRRNCN 
Nematostella_vectensis_369      PDWIYSTS---QNKLYIKPQTPCPMKFSVT-------------------- 
Drosophila_melanogaster         SLWMYSIP---LNKLYIRMNKAFNVDVQFKS------------------- 
Monosiga_brevicollis            LMIQYSPQ---LGRFFVHVNADVVLKIVLAR------------------- 
Caenorhabditis_elegans          SDMAFAISSEHEKYLWTKMGCLVPIQVKWKLDKR---------------- 
                                    ::        :: .      :..                       
Homo_sapiens                    -----STPPPGTRVRAMAIYKQSQHMTEVVRRCPHHER----CSDSDGLA 
Rattus_norvegicus               -----STPPPGTRVRAMAIYKKSQHMTEVVRRCPHHER----CSDGDGLA 
Danio_renio                     -----VAPPQGSVVRATAIYKKSEHVAEVVRRCPHHER----TPDGDNLA 
Ciona_intestinalis_489          -----RPPPNGCVVRVMPVFKRPEHVTDIVTRCPNHK----IPDQAQHIP 
Ciona_intestinalis_419          -----PQPPSGCVIRAIPVFEKPNNVTEIVTRCFNHRNEC-RTESSDSNT 
Nematostella_vectensis_378      -----VKPPPGSYLRGVAVFKGSTNLHDIVKRCPNHM-----ETSQDGQE 
Trichoplax_adhaerens            QLIIPGEPPANSYIRAYVMYTKPQDVYEPVRRCPNHAL-----RDQGKYE 
Nematostella_vectensis_369      -----GCVPPGTFIRAIPIFKLPEHAKDVVRCCPNHTLLE---QSNRDHP 
Drosophila_melanogaster         -----KMPIQPLNLRVFLCFSN--DVSAPVVRCQNHLS-V-EPLTANNAK 
Monosiga_brevicollis            ------APPKGTDLVFRLRYALPEHRKTRVETCVTHQQ----AGSHFFGA 
Caenorhabditis_elegans          -----HFNSNLSLRIRFVKYDKKENVEYAIRNPRSDVMKCRSHTEREQHF 
                                                   :    .    :     .              
B
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Homo_sapiens                    PPQHLIRVE--GNLRVEYLDDRNT----FRHSVVVPYEPPE----VGSDC 
Rattus_norvegicus               PPQHLIRVE--GNPYAEYLDDRQT----FRHSVVVPYEPPE----VGSDY 
Danio_renio                     PAGHLIRVE--GNQRANYREDNIT----LRHSVFVPYEAPQ----LGAEW 
Ciona_intestinalis_489          HSQHLIRAEMPGENPAIYNVAMD-----GRENVAVMFERPQ----IGAEY 
Ciona_intestinalis_419          PNSHLIRVESKSNN-IQYCLTHE-----GRECVVVPYEPPH----SGSEY 
Nematostella_vectensis_378      KVSHFMRSNNPSAR---YNVCPES----GRHSILIPYTGPQ----VGTEF 
Trichoplax_adhaerens            SSDHILRCE---SQRAEYYEDTS-----GRHSVRVPYTAPA----VGELR 
Nematostella_vectensis_369      AMAHFIRSD---NPRAEYERCAQS----GRLSVKIPFHVTQGSI-SEEII 
Drosophila_melanogaster         MRESLLRSE---NPNSVYCGNAQGKGISERFSVVVPLNMSRSVTRSGLTR 
Monosiga_brevicollis            PHNHLMSIN---REHVTYDTDSTG-----HHYARVALDQFP----FTDNV 
Caenorhabditis_elegans          PFDSFFYIR---NSEHEFSYSAEK----GSTFTLIMY--------PGAVQ 
                                    ::           :                :               
Homo_sapiens                    TTIHYNYMCNSSCM--GGMNRRPILTIITLEDSSGNLLGRNSFEVRVCAC 
Rattus_norvegicus               TTIHYKYMCNSSCM--GGMNRRPILTIITLEDSSGNLLGRDSFEVRVCAC 
Danio_renio                     TTVLLNYMCNSSCM--GGMNRRPILTIITLETQEGQLLGRRSFEVRVCAC 
Ciona_intestinalis_489          TTVLYKFMCLSSC--VGGINRRPLNAVFNLENAEGQVLGRRVVEVRVCSC 
Ciona_intestinalis_419          MALLYRFMCLSSCRTETGINRRPLLTIFNLESETGELLGKRVVSTRICAC 
Nematostella_vectensis_378      VTEMFAFMCFSSCP--SGPSRRPVEIIFTLE-KDGQTLGRQVVEIRVCAC 
Trichoplax_adhaerens            STLLYQFMCFSSCS--GSINRRPIELVITLENGTN-VLGRKKVEVRVCAC 
Nematostella_vectensis_369      VHELFSFVCNNSCG---GLNRRAIQIVFTLEQAVAVSCWRCSIETRVCAC 
Drosophila_melanogaster         QTLAFKFVCQNSCI-----GRKETSLVFCLEKACGDIVGQHVIHVKICTC 
Monosiga_brevicollis            YSVPLRFHCFSSCP--GSIARRMMQLMVYLEHSEH-ILGITSVDCRCCAC 
Caenorhabditis_elegans          ANFDIIFMCQEKCLDLDDRRKTMCLAVFLDDENGNEILHAYIKQVRIVAY 
                                      : * ..*       :     :.  :              :  : 
Homo_sapiens                    PGRDRRTEEENLRKKG 
Rattus_norvegicus               PGRDRRTEEENFRKKE 
Danio_renio                     PGRDRKTEESNFKKDQ 
Ciona_intestinalis_489          PGRDRSQEEKRKRTAE 
Ciona_intestinalis_419          PGRDRTQEEEKKNVT- 
Nematostella_vectensis_378      PGRDRKSDEKLLLGEA 
Trichoplax_adhaerens            PGRDRSNEERAAMKSE
Nematostella_vectensis_369      PGRDSKQDNEAVSRPG 
Drosophila_melanogaster         PKRDRIQDERQLNSKK 
Monosiga_brevicollis            PGRDRLSAEKRQQRNS 
Caenorhabditis_elegans          PRRDWKNFCEREDAKQ 
                                * **   
Figure 7. A) P53-like proteins among various species throughout evolution. Either protein, nucleotide or gene accession 
numbers of protein sequences which were used are specified. The overall percentage of disorder was calculated with PONDR 
VL-XT and identity scores were obtained from multiple sequence alignments using CLUSTAL 2.0.12. B) Multiple sequence 
alignment of human p53-related DBDs (“*” for identical residues in all sequences; “:” conserved substitutions; “.” semi-
conserved substitutions).
Conclusion: drug discovery and 
disordered motifs 
We have described the emerging view of the linear or 
disordered domain in the formation of protein-protein 
interactions in eukaryotes and how this can impact on 
our understanding of the protein interaction landscape 
that captures p53. Defining the global interactome of a 
target protein is an emerging technological challenge 
in the field of systems biology. Such knowledge has a 
potentially high impact in human medicine where rate-
limiting nodes can be identified as a focus of novel 
diagnostic or therapeutic advances. One significant 
insight into the nature of a protein-protein interaction 
in the last decade has been the concept that a large 
proportion of the polypeptide sequence information 
in higher eukaryotes is intrinsically disordered 
thus providing a template for “weak” regulatory, 
combinatorial, and specific PPIs to occur in signal 
transduction [81]. A second advance was the realisation 
that a significant number of PPIs occur via a linear amino 
acid motif that provides opportunities for hotspots to be 
identified in a PPI and thus the emerging view is that 
drugging PPIs form a new and untapped landscape in the 
drug discovery field [82]. Thus, identifying approaches 
that can capture the dynamic linear motif interactome 
of a target protein provides another avenue to build 
systems map of a protein. Such screens have expanded 
on the potential number of interactors to hundreds and 
highlight the utility in approaches that capture weak but 
regulatory PPIs.  
The p53 and MDM2 axis form an evolutionary ancient 
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Table 1. List of p53 peptides or domains co-crystallised with binding partners. 
Molecule Ligand PDB code
P53 N-terminal peptide MDM2 1YCR
MDM4 3DAB
histone acetyltransferase p300 2K8F
replication protein A 70 2B3G
RNA polymerase II transcription factor B 2GS0
P53 C-terminal peptide S100ββ 1DT7
Sirtuin 2 1MA3
CREB-binding protein 1JSP
Cyclin A (-CDK2) 1H26
14-3-3 3LW1
USP7 2FOJ/2FOO
histone acetyltransferase GCN5 1Q2D
methyltransferase SET9 1XQH
P53-derived O-GlcNAc peptide O-GlcNAcase 2YDR
Monomethylated p53 peptide methyltransferase SMYD2 3S7D
P53 C-terminal dimethylated peptide DNA repair factor 53BP1 3LGF
P53 DNA binding domain DNA repair factor 53BP1 1GZH
P53 DNA binding domain SV40 large T-antigen 2H1L
P53 tetramerisation peptide P53 tetramerisation peptide 2J0Z
prototype protein-protein interaction pair that exploits 
the intrinsically disordered motif of one protein and a 
peptide-binding pocket interface in another. MDM2 
binds to an intrinsically disordered peptide motif in the 
p53 TAD1 domain that can be mimicked by the small 
molecule Nutlin-3. This small molecule can activate 
p53 [56] and recent clinical trials of an MDM2 peptide-
binding mimetic drug-lead show promising responses in 
Table 2. List of peptide and peptide-derived molecules that can activate p53 through PPI disruption. 
Molecule Ligand Drugging strategy
P53 N-terminal peptide [40] MDM2 p53 hydrogen-bond-surrogate α-helix [85]
p53 hydrocarbon-stapled α-helix (3V3B) [86]
p53-mimicking small molecule Nutlin (1RV1) [87]
cell-penetrable spiroligomer α-helix [88]
p53-based small molecule MI-219 [89]
p53 peptidomimetic trisaccharide [90]
P53 N-terminal peptide [91] MDM4 Optimized p53 peptide [92] targeting MDM2/MDM4
P53 peptide from tetramerisation domain [93] CDK2-Cyclin A/B Based on CDK2 docking site
P53 C-terminal peptide [94] Core domain of 
P53 mutant
Activates p53 through displacement of the negative 
regulatory C-terminal domain
CDB3 peptide [95] P53 mutant Based on p53C-53BP2 complex (1YCS)
Optimized AGR2-binding penta-peptide [96] P53 Stabilises p53 and increases its nuclear localisation
PKCα-derived peptide [97] Tetrameric p53 Regulate oligomerisation state of p53
clinical trials of human sarcoma containing an amplified 
mdm2 gene [83] and how a p53-dervied peptide motif 
can be developed into an oncogenic protein inhibitor. 
Although there are almost 500 p53 interacting proteins 
published with little information on the mode of binding 
at the PPI interface, there are a growing list of PPIs that 
form crystal structures giving rise to structural modelling 
possibilities (Figure 4 and Tables 1 and 2). As the drug 
discovery field is acknowledging ever more that protein-
protein interactions form an untapped landscape for 
therapeutic development [84], it is highly likely that other 
oncogenic protein-protein interactions between linear 
intrinsically disordered motifs of p53 and peptide binding 
pockets in target proteins will emerge into drug discovery 
programmes in the future. 
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